Table 4 Characteristics of published completed trials
From: Therapeutic role of corticosteroids in COVID-19: a systematic review of registered clinical trials
Ref | Country | Year of publication | Steroid used | Primary outcomes | P value |
|---|---|---|---|---|---|
[24] | China | 2020 | Methylprednisolone 396 of 409 [96.8%], dexamethasone 32 of 409 [7.8%] patients—hydrocortisone equivalent | Corticosteroid therapy had higher 28-day mortality rate. Delay in SARS-CoV RNA clearance (P = 0.00017) | < 0.05 |
[25] | USA | 2020 | Hydrocortisone 200 mg/day and tapered till 50 mg/day | Treatment failure occurred in hydrocortisone patient is 42.1% compared to placebo 50.7% | < 0.045 |
[26] | Netherlands | 2020 | Methylprednisolone 80 mg, 250 mg | There was a 79% higher likelihood of two stage improvement in respiratory status | < 0.025 |
[27] | USA | 2020 | Hydrocortisone 50 mg, 100 mg | The in-hospital death in treatment group is 30% and 26% compared to no hydrocortisone, i.e. 33% | < 0.05 |